Established in March 2023, the Sino-European Center of Biomedicine and Health (SEC) was jointly founded by the Luohu District People’s Government of Shenzhen and the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. As an innovation platform in advanced medicine, SEC plays a key role in supporting the Luohu District government’s implementation of Shenzhen’s ‘20+8’ strategic industrial clusters in the healthcare sector, realizing the concept of ‘integrated design and coordinated advancement of technology and industry’.

With the vision of “Advanced Medicine From Here to the World,” SEC is committed to empowering the high-quality development of the healthcare and consumer medical sectors through biotechnology. Focusing on three core areas: Advanced Therapy Medicinal Products (ATMPs), Digital Health, and Longevity Medicine, the center is built on four pillars: establishing high-level research and innovation bases, building an international hub for translational medicine, fostering clusters of high-potential enterprises, and creating a dynamic commercial ecosystem. By fostering close collaboration between entrepreneurs and scientists, it advances an integrated model of innovation, translation, and industrialization, accelerating commercialization and shaping a new global paradigm for the life and health industries in partnership with Luohu District.